Published in J Nucl Med on August 01, 1992
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Mesoscale iron enrichment experiments 1993-2005: synthesis and future directions. Science (2007) 4.92
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J Biol Chem (2001) 3.76
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Molecular analysis of aldolase B genes in hereditary fructose intolerance. Lancet (1990) 3.28
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol Microbiol (2000) 2.59
Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med (1992) 2.56
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry (2001) 2.32
The mental representation of hand movements after parietal cortex damage. Science (1996) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
Frequency of the DYT1 mutation in primary torsion dystonia without family history. Arch Neurol (2000) 2.17
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Mol Microbiol (1999) 2.00
The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain (1999) 2.00
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A (2000) 1.97
X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology (1998) 1.96
Superior temporal sulcus anatomical abnormalities in childhood autism: a voxel-based morphometry MRI study. Neuroimage (2004) 1.93
Assessing tremor severity. J Neurol Neurosurg Psychiatry (1993) 1.92
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem (1992) 1.91
Structural abnormalities in the cerebellum and sensorimotor circuit in writer's cramp. Neurology (2007) 1.91
A novel DCC mutation and genetic heterogeneity in congenital mirror movements. Neurology (2011) 1.88
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology (2000) 1.85
Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1994) 1.85
Parkinson's disease and sleepiness: an integral part of PD. Neurology (2002) 1.85
Peduncular 'rubral' tremor and dopaminergic denervation: a PET study. Neurology (1995) 1.84
Eye movements in parkinsonian syndromes. Ann Neurol (1994) 1.84
Cortical control of reflexive visually-guided saccades. Brain (1991) 1.84
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol (1996) 1.77
A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology (2008) 1.74
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Recovery from nonfluent aphasia after melodic intonation therapy: a PET study. Neurology (1996) 1.73
Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology (1987) 1.70
Pallidal stimulation for Parkinson's disease. Two targets? Neurology (1997) 1.69
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res (1983) 1.67
Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet (1998) 1.64
Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation (1993) 1.62
Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry (2005) 1.60
Arbitrarily primed polymerase chain reaction as a rapid method to differentiate crossed from independent Pseudomonas cepacia infections in cystic fibrosis patients. J Clin Microbiol (1993) 1.60
FDG accumulation and tumor biology. Nucl Med Biol (1998) 1.59
Confirmation of linkage of Friedreich ataxia to chromosome 9 and identification of a new closely linked marker. Genomics (1989) 1.59
Lateralization of speech and auditory temporal processing. J Cogn Neurosci (1998) 1.58
Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol (1978) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci (1999) 1.58
Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol (1999) 1.57
Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum Mol Genet (1998) 1.56
Failure of long-term pallidal stimulation corrected by subthalamic stimulation in PD. Neurology (2000) 1.55
TENS is harmful in primary writing tremor. Clin Neurophysiol (2010) 1.52
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
A primal sketch of the cortex mean curvature: a morphogenesis based approach to study the variability of the folding patterns. IEEE Trans Med Imaging (2003) 1.49
Linkage of a new locus for autosomal dominant familial spastic paraplegia to chromosome 2p. Hum Mol Genet (1994) 1.49
Absence of linkage to 8q24 in a European family with familial adult myoclonic epilepsy (FAME). Neurology (2002) 1.48
Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology (2000) 1.47
Ropinirole without levodopa in Parkinson's disease. Lancet (1990) 1.46
Role of pontine nuclei damage in smooth pursuit impairment of progressive supranuclear palsy: a clinical-pathologic study. Neurology (1994) 1.46
Delayed response tasks and prefrontal lesions in man--evidence for self generated patterns of behaviour with poor environmental modulation. Neuropsychologia (1993) 1.45
[The L-dopa test in Parkinson's disease]. Rev Neurol (Paris) (1985) 1.42